期刊文献+

肾嫌色细胞癌33例临床分析 被引量:6

Study of 33 cases of chromophobe renal cell carcinoma
原文传递
导出
摘要 目的 分析肾嫌色细胞癌的临床和病理特征,探讨该病的治疗及预后,提高对该病的诊治水平.方法 回顾性分析2009年1月至2013年9月收治的33例肾嫌色细胞癌患者的资料.男13例,女20例;年龄19~76岁,平均55岁.病变位于左肾18例,右肾15例;33例术前行B超检查,30例行CT扫描,3例行MRI检查.结果 33例均行手术治疗,其中行根治性肾切除术15例,保留肾单位手术5例,腹腔镜下根治性肾切除术11例,腹腔镜下保留肾单位手术2例.术中均未见肾门淋巴结肿大.肿瘤平均直径5.2 cm.病理分期:23例pT1N0M0,6例pT2N0M0,2例pT3N0M0,2例pT1N0M1.Fuhrman分级:Ⅰ级1例,Ⅱ级19例,Ⅲ级9例,Ⅳ级4例.26例患者获得随访,中位随访时间24个月,无出现复发或因肿瘤导致死亡者.结论 肾嫌色细胞癌是肾细胞癌的一种少见类型,手术切除是主要的治疗方式.肾嫌色细胞癌较少复发和转移,预后良好. Objective To improve the diagnosis and treatment of chromophobe renal cell carcinoma (CRCC),we investigated and summarized the clinical and pathological features of CRCC patients in our hospital.Methods We have retrospectively analyzed the clinical features of 33 CRCC patients.The mean age of these patients at diagnosis was 55 years-old,including 13 males and 20 females.All tumors were localized unilaterally,with 18 in left kidney and 15 in right kidney.Ultrasonography was performed on all patients,CT scan on 30 patients and MRI on 3 patients.Results All of the patients underwent surgery.Fifteen patients underwent radical nephrectomy,11 patients underwent laparoscopic radical nephrectomy,5 patients underwent nephron sparing surgery and 2 patients underwent laparoscopic nephron sparing surgery.The average diameter of tumors was 5.2 cm.Among them,23 patients were at pT1N0M0,6 at pT2N0M0,2 at T3N0M0 and 2 at T3N0M0.The pathologic Fuhrman grade of CRCC was G1 in 1 case,G2 in 19 cases,G3 in 9 cases and G4 in 4 cases.Twenty-six patients were followed up with a mean duration of 24 months and no local recurrence was found.Conclusions CRCC is a rare subtype of renal cell carcinoma with little recurrence and metastasis.Surgery was the common treatment for CRCC.Usually,CRCC patients have favorable prognosis.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2014年第2期91-94,共4页 Chinese Journal of Urology
关键词 肾细胞 嫌色细胞癌 诊断 治疗 预后 Carcinoma, renal cell Chromophobe cell carcinoma Diagnosis Treatment Prognosis
  • 相关文献

参考文献3

二级参考文献27

  • 1刘雨,孙光,徐勇,畅继武,韩瑞发,马腾骧.肾嫌色细胞癌(附15例报告)[J].中华泌尿外科杂志,2004,25(9):611-612. 被引量:12
  • 2杨培谦,杜林栋,黄受方,吕文成.肾嫌色细胞癌临床与病理学特点分析[J].中华泌尿外科杂志,2005,26(6):399-401. 被引量:15
  • 3Obara W, Mizutani Y, Oyama C, et al. Prospective study of combined treatment with interferon alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol, 2008, 15: 794-799.
  • 4Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioe conomic burden of metastatic renal cell carcinoma (mRCC) : a literature review. Cancer Treat Rev, 2008, 34:193-205.
  • 5Taari K, Perttila I, Nisen H. Laparoscopic versus open nephrectomy for renal cell carcinoma? Scand J Surg, 2004, 93:132-136.
  • 6Rubinstein M, Moinzadeh A, Colombo JR Jr. Energy sources for laparoscopic partial nephrectomy critical appraisal. Int Braz J Urol, 2007, 33:3-10.
  • 7Chapman TN, Sharma S, Zhang S. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology, 2008, 71:287-291.
  • 8Godoy G, O'Malley RL, Taneja SS. Lymph node dissection during the surgical treatment of renal cancer in the modern era. Int Braz J Urol, 2008, 34: 132-142.
  • 9Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J, 2008, 14: 308-314.
  • 10Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am, 2008, 35: 673-678.

共引文献105

同被引文献56

  • 1李清海,严福华,徐鹏举,侯君,周建军,周梅玲.肾嫌色细胞癌的影像表现与病理对照分析[J].中华放射学杂志,2007,41(3):259-263. 被引量:42
  • 2Cho HJ,Baek KE,Park SM,et al.RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer[J].Clin Cancer Res,2009,15(8):2612-2619.
  • 3Liu S,Cui H,Li Q,et al.RhoGDI2 is expressed in human trophoblasts and involved in their migration by inhibiting the activation of RACl.Biol Reprod, 2014,90(4):88.
  • 4Gildea JJ,Seraj MJ,Oxford G,et al.RhoGDI2 is an invasion and metastasis suppressor gene in human cancer[J],Cancer Res,2002,62(22):6418-6423.
  • 5Stevens EV,Banet N,Onesto C,et al.RhoGDl2 antagonizes ovarian carcinoma growth,invasion and metastasis[J].Small GTPases,2011,2(4):202-210.
  • 6Mack NA,Georgiou M.The interdependence of the Rho GTPases and apicobasal cell polarity[J].Small GTPases,2014,5(2):1-16.
  • 7Cho H J,Park S M,Kim I K,et al.RhoGDl2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells[J].Oncotarget,2014,5(6):1554-1564.
  • 8Xu R,Dong Y,Wang L,et al.TAT-RhoGDI2,a novel tumor metastasis suppressor fusion protein:expression,purification and functional evaluation[J].Appl Microbiol Biotechnol,2014,98(23):9633-9641.
  • 9Li X,Wang J,Zhang X,et al.Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma.Ann Surg Oncol.2012,19(1):145-153.
  • 10Yi B,Hu Y,Qin G,et al.Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma[J}.Int J Mol Med,2014,34(1):205-212.

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部